On June 16, 2023, after the market closure GUFIC Biosciences Ltd has reported in regular filing that it has received approval from National Medical Products Administration (NMPA), China for their product PRILOCAINE (API) which is an amide-type local anaesthetic of fast onset and intermediate duration of action. This approval shall help commercialization of the PRILOCAINE …